McDonald’s Corporation (NYSE: MCD) beat revenue and earnings estimates for the fourth quarter of 2019. Analysts had forecast earnings of $1.96 per share on revenue of $5.30 billion. Despite the beat, shares were down 1.2% in premarket hours on Wednesday.
Consolidated revenues increased 4% year-over-year to $5.35 billion. Systemwide sales increased 6%. Global comparable sales grew 5.9%.

GAAP net income rose 11% to $1.57 billion while EPS increased 14% to $2.08. Adjusted EPS was $1.97.
CFO Kevin Ozan said, “Our Velocity Growth Plan helped produce strong operating performance over the past several years, and our underlying financial strength continues to build long-term value for our shareholders. As we begin 2020, we remain committed to our capital allocation philosophy to reinvest in the business to drive profitable growth and return all free cash flow to shareholders through a combination of dividends and share repurchases.”
Sales by company-operated restaurants remained flat at $2.36 billion while revenues from franchised restaurants increased 7% to $2.98 billion.
Also see: McDonald’s Q4 2019 Earnings Preview
Comparable sales increased 6.2% in the International Operated segment, 5.1% in the US and 6.6% in the International Developmental Licensed segment.
McDonald’s returned $2.3 billion to shareholders through share repurchases and dividends during the fourth quarter and $8.6 billion for the full year, marking the successful achievement of its targeted return of $25 billion for the three-year period ended 2019.
Get access to timely and accurate verbatim transcripts that are published within hours of the event.
Most Popular
Key takeaways from JM Smucker’s (SJM) Q4 2025 earnings report
Shares of The J.M. Smucker Co. (NYSE: SJM) plunged 15% on Tuesday after the company delivered mixed results for the fourth quarter of 2025. While earnings came ahead of expectations,
J.M. Smucker (SJM) Q4 2025 Earnings: Key financials and quarterly highlights
The J.M. Smucker Co. (NYSE: SJM) reported its fourth quarter 2025 earnings results today. Net sales was $2.1 billion, down 3% year-over-year. Comparable net sales decreased 1%. Net loss was
Plus Therapeutics CEO: Lead candidate REYOBIQ demonstrates strong safety and efficacy in early trials
Plus Therapeutics (NASDAQ: PSTV) is a pharmaceutical company engaged in the development of targeted radiotherapeutics for difficult-to-treat cancers. Currently, it is advancing a pipeline of product candidates with lead programs